On the one hand, we have identified a new non-invasive diagnostic biomarker LEAP-2 for MAFLD and explored its differential expression in healthy populations, MAFLD, and other liver diseases; On the other hand, we further confirmed the role of CK18 M65 in distinguishing healthy individuals from MAFLD. Here, LEAP2 is linked to liver disorder.